尔康制药(300267.SZ)发布上半年业绩,归母净利润3763.46万元,增长497.36%
Core Viewpoint - Erkang Pharmaceutical (300267.SZ) reported a revenue of 682 million yuan for the first half of 2025, reflecting a year-on-year growth of 9.74% [1] - The net profit attributable to shareholders reached 37.63 million yuan, marking a significant year-on-year increase of 497.36% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 33.02 million yuan, showing a remarkable year-on-year growth of 1357.97% [1] - The basic earnings per share stood at 0.0182 yuan [1]